Generalized thyroid hormone resistance (GTHR) is a familial syndrome characterized by elevated levels of free thyroid hormones, resistance to thyroid hormone action, and inappropriately normal or elevated levels of thyroid-stimulating hormone. Kindreds with GTHR have variables clinical pathology presumably related to differences in regulation by thyroid hormones. Linkage studies in several kindreds with GTHR suggest that abnormalities in the C-erbA-beta thyroid hormone receptor gene are responsible for the syndrome. It has been hypothesized that the mutant receptors may interact with the wild-type receptor and inhibit its function, thus behaving as dominant negative mutations. This project will elucidate the molecular defects in C-erbA-beta in four different kindreds, A, D, S, and W with thyroid hormone resistance. These kindreds have variant phenotypes with affected members from some of these kindreds exhibiting short stature, mental retardation,and hyperactivity. C-erbA-beta cDNAs will be obtained by reverse-transcription-polymerase chain reaction amplifications from fibroblast total RNA and sequenced. Changes from the published wild-type sequence that alter amino acid structure will be verified in genomic sequence, and tested as mutations by measuring the frequency of the sequence alterations in random alleles using allelic specific hybridization. Mutations will be tested for linkage to GTHR, and by constructing mutant receptors and measuring their T3-binding- affinity in vitro. Also, Scatchard plots of mixtures of the wild-type beta-receptor and mutant receptors will be generated to see if a dominant negative effect can be detected in vitro. Finally, transformed fibroblast lines will be established from these kindreds and the relative steady-state levels of C-erbA-beta 1, and C-erbA-alpha1, and C-erbA alpha2, measured in primary and transformed fibroblasts of affected and unaffected kindred members. Correlation of the c-erbA-beta mutations with the tissue-specific clinical pathology in these four kindreds will help elucidate the tissue- specific roles of the beta-receptor. This project will also provide genetic tests for GTHR for neonates within the kindreds which may have therapeutic value in the future. Isolation and characterization of these putative, mutant beta-receptors will provide new insights into the complex mechanisms of thyroid hormone action in man.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29DK042807-05
Application #
2142559
Study Section
Endocrinology Study Section (END)
Project Start
1990-08-01
Project End
1996-01-01
Budget Start
1994-08-01
Budget End
1996-01-01
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
East Carolina University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Greenville
State
NC
Country
United States
Zip Code
27858
Flynn, T R; Hollenberg, A N; Cohen, O et al. (1994) A novel C-terminal domain in the thyroid hormone receptor selectively mediates thyroid hormone inhibition. J Biol Chem 269:32713-6
Usala, S J (1994) Resistance to thyroid hormone in children. Curr Opin Pediatr 6:468-75
Hao, E; Menke, J B; Smith, A M et al. (1994) Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities. Mol Endocrinol 8:841-51
Geffner, M E; Su, F; Ross, N S et al. (1993) An arginine to histidine mutation in codon 311 of the C-erbA beta gene results in a mutant thyroid hormone receptor that does not mediate a dominant negative phenotype. J Clin Invest 91:538-46
Klann, R C; Torres, B; Menke, J B et al. (1993) Competitive polymerase chain reaction quantitation of c-erbA beta 1, c-erbA alpha 1, and c-erbA alpha 2 messenger ribonucleic acid levels in normal, heterozygous, and homozygous fibroblasts of kindred S with thyroid hormone resistance. J Clin Endocrinol Metab 77:969-75
Ways, D K; Qin, W; Cook, P et al. (1993) Dominant and nondominant negative C-erbA beta 1 receptors associated with thyroid hormone resistance syndromes augment 12-O-tetradecanoyl-phorbol-13-acetate induction of the collagenase promoter and exhibit defective 3,5,3'-triiodothyronine-mediated repre Mol Endocrinol 7:1112-20
Refetoff, S; Weiss, R E; Usala, S J (1993) The syndromes of resistance to thyroid hormone. Endocr Rev 14:348-99
Meier, C A; Dickstein, B M; Ashizawa, K et al. (1992) Variable transcriptional activity and ligand binding of mutant beta 1 3,5,3'-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol Endocrinol 6:248-58
Cugini Jr, C D; Leidy Jr, J W; Chertow, B S et al. (1992) An arginine to histidine mutation in codon 315 of the c-erbA beta thyroid hormone receptor in a kindred with generalized resistance to thyroid hormones results in a receptor with significant 3,5,3'-triiodothyronine binding activity. J Clin Endocrinol Metab 74:1164-70
Burman, K D; Djuh, Y Y; Nicholson, D et al. (1992) Generalized thyroid hormone resistance: identification of an arginine to cystine mutation in codon 315 of the c-erb A beta thyroid hormone receptor. J Endocrinol Invest 15:573-9

Showing the most recent 10 out of 13 publications